Stock News

aTyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT™ Clinical Trial Participants
aTyr Pharma to Present Posters Highlighting Importance of Neuropilin-2 in Immune Regulation at Keystone Symposia on Myeloid Cell Diversity
aTyr Pharma Announces Howard University President Emeritus Dr. Wayne A. I. Frederick as Advisor
aTyr Pharma Presents Poster Demonstrating Preclinical Effects of Efzofitimod in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated ILD at the ACR Convergence 2023
aTyr Pharma Announces Third Quarter 2023 Results and Provides Corporate Update
aTyr Pharma to Present at November Investor Conferences
aTyr Pharma Announces Dosing of First Patient in Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Patients with SSc-ILD
aTyr Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
aTyr Pharma Announces Second Quarter 2023 Results and Provides Corporate Update
7 Growth Stocks That AI Predicts Will Deliver Triple-Digit Returns in 2023
European Commission Grants Orphan Drug Designation for aTyr Pharma’s Efzofitimod for Treatment of Systemic Sclerosis
aTyr Pharma to Present on Lead Therapeutic Candidate Efzofitimod at the World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) Conference
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

As seen on...